Histosonics Announces $100 Million In Financings And New Appointment To Its Board Of Directors

Dec 13, 2022•about 3 years ago

Amount Raised

$100 Million

PlymouthHealthcare

Investors

State Of Wisconsin Investment BoardYonjin VentureLumira VenturesVenture Investors

Description

HistoSonics, Inc. (www.histosonics.com), the developer of a non-invasive, novel sonic beam therapy, announced today that it has raised $85 million in a financing led by Johnson & Johnson Innovation - JJDC, Inc., with participation from existing investors including Venture Investors, Lumira Ventures, Yonjin Venture, and the State of Wisconsin Investment Board, among others. Concurrently, HistoSonics also secured a commitment for a $15 million expansion of the amount available under its existing debt facility with Signature Bank, which the company may access to accelerate strategic projects. Proceeds of the financings will be used to support HistoSonics anticipated commercial launch, additional clinical trials, and to expand application development of EdisonTM, the company's novel histotripsy therapy platform, throughout the body.

Company Information

Company

HistoSonics

Location

16305 36th Avenue North, 300

Plymouth, Minnesota, United States

About

HistoSonics is a growth phase company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquefy and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company’s new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today’s interventional and surgical modalities.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends